Evidence map›Paper›PMID 23688691›Full record

ReviewThe Psychiatric clinics of North America2013

Neurologic manifestations of chronic methamphetamine abuse.

Daniel E Rusyniak

Open access · greenAbstract readReview
In one paragraph

Review in The Psychiatric clinics of North America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 3 pooled it
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 3 syntheses or guidelines pooled it, 158 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. A Rare Phenomenon, Recurrent Acute Dystonia after Withdrawal of 'Methylphenidate-immediate Release Form': A Pediatric Case with ADHD.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2024
    Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Vision health perspectives onFrontiers in toxicology · 2023
    Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Daniel E RusyniakDepartment of Emergency Medicine, Indiana University School of Medicine, 1050 Wishard Boulevard, Room 2200, Indianapolis, IN 46202, USA. drusynia@iupui.edu
Indiana University – Purdue University Indianapolis · US

Funding

CNS circuitry and receptors mediating the effects of MDMAR01DA026867 · NIDA · INDIANA UNIVERSITY INDIANAPOLIS · PI RUSYNIAK, DANIEL E · 2010 to 2014
$1.6M
Ecstasy and the Dorsomedial HypothalamusK08DA020484 · NIDA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI RUSYNIAK, DANIEL E · 2006 to 2010
$906k
NIDA NIH HHS DA020484NIDA NIH HHS DA026867NIDA NIH HHS K08 DA020484NIDA NIH HHS R01 DA026867
6 · The paper itself

Abstract

The drug with perhaps the greatest impact on the practice of Psychiatry is Methamphetamine. By increasing the extracellular concentrations of dopamine while slowly damaging the dopaminergic neurotransmission, Meth is a powerfully addictive drug whose chronic use preferentially causes psychiatric complications. Chronic Meth users have deficits in memory and executive functioning as well as higher rates of anxiety, depression, and most notably psychosis. It is because of addiction and chronic psychosis from Meth abuse that the Meth user is most likely to come to the attention of the practicing Psychiatrist/Psychologist. Understanding the chronic neurologic manifestations of Meth abuse will better arm practitioners with the diagnostic and therapeutic tools needed to make the Meth epidemic one of historical interest only.

Indexed as

Amphetamine-Related DisordersCognition DisordersDental CariesDyskinesia, Drug-InducedHumansMethamphetamineParesthesiaParkinson Disease, SecondaryPsychoses, Substance-InducedStereotyped BehaviorMethamphetamine

Identifiers

PMID23688691
PMCPMC3764482
OpenAlexW2004664745

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.